×

MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY

  • US 20190000944A1
  • Filed: 12/21/2016
  • Published: 01/03/2019
  • Est. Priority Date: 12/22/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a subject having a disease associated with mesothelin expression, comprising administering to the subjecti) a cell, e.g., a population of immune effector cells, comprising, e.g., expressing, a chimeric antigen receptor (CAR), wherein the CAR comprises a mesothelin binding domain, a transmembrane domain, and an intracellular signaling domain;

  • andii) a PD-L1 inhibitor, wherein the PD-L1 inhibitor is administered prior to administration of the cell comprising a CAR.

View all claims
  • 12 Assignments
Timeline View
Assignment View
    ×
    ×